Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

2.

Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.

Van Poznak C, Cross SS, Saggese M, Hudis C, Panageas KS, Norton L, Coleman RE, Holen I.

J Clin Pathol. 2006 Jan;59(1):56-63.

3.

Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.

Nyambo R, Cross N, Lippitt J, Holen I, Bryden G, Hamdy FC, Eaton CL.

J Bone Miner Res. 2004 Oct;19(10):1712-21. Epub 2004 Jul 7.

5.

Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.

Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG.

Anticancer Res. 2013 Jan;33(1):199-206.

PMID:
23267146
7.

Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.

Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC.

J Cell Biochem. 2009 Sep 1;108(1):106-16. doi: 10.1002/jcb.22232.

PMID:
19544400
8.

Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease.

Sood SK, Balasubramanian S, Higham S, Fernando M, Harrison B.

World J Surg. 2011 Sep;35(9):1984-92. doi: 10.1007/s00268-011-1185-5.

PMID:
21748518
10.
11.
12.

Association between ligands and receptors related to the progression of early breast cancer in tumor epithelial and stromal cells.

Labovsky V, Martinez LM, Davies KM, García-Rivello H, Calcagno Mde L, Matas A, Fernández Vallone VB, Wernicke A, Choi H, Chasseing NA.

Clin Breast Cancer. 2015 Feb;15(1):e13-21. doi: 10.1016/j.clbc.2014.05.006. Epub 2014 Jun 21.

PMID:
25044301
13.

Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.

Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA.

Cancer. 2006 Jul 15;107(2):289-98.

14.

Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival?

Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL.

Breast Cancer Res Treat. 2005 Aug;92(3):207-15.

PMID:
16155791
15.

Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis.

Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I.

Breast Cancer Res Treat. 2004 Aug;86(3):269-79.

PMID:
15567943
17.
18.

Osteoprotegerin is expressed in colon carcinoma cells.

Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B.

Anticancer Res. 2005 Nov-Dec;25(6B):3809-16.

20.

The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage.

Komuro H, Olee T, Kühn K, Quach J, Brinson DC, Shikhman A, Valbracht J, Creighton-Achermann L, Lotz M.

Arthritis Rheum. 2001 Dec;44(12):2768-76.

PMID:
11762937

Supplemental Content

Support Center